<DOC>
	<DOCNO>NCT00817687</DOCNO>
	<brief_summary>This 2 arm study evaluate impact fibrosis week 52 early biopsy , patient receive kidney transplant expand criterion donor . Patients randomize one two group ; first group biopsy day 10 , second group receive standard management . All patient give CellCept standard care . The anticipated time study treatment 1 year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Impact Early Biopsy Patients Treated With CellCept ( Mycophenolate Mofetil ) After Kidney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; receipt initial cadaveric kidney transplant ; receipt graft biopsy ; receipt 'marginal ' kidney transplant . receipt second kidney transplant ; receipt multiorgan transplant double kidney transplant ; malignant tumor , history cancer past 5 year , successfully treat basal cell spinocellular cancer cancer situ cervix ; replicate hepatitis B and/or C , HIV positive serology .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>